Eli Lilly (NY:LLY)

OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder ↗

Topics Artificial Intelligence

January 12, 2026

Stargardt disease is a form of inherited macular degeneration, affecting more than 100,000 people in the U.S. and Europe combined.

ABVX Soars Pre-Market On Reports Of $17.5 Billion Eli Lilly Takeover Interest ↗

January 12, 2026

What does the new year bring to investors?

An Investor's Guide to 2026 ↗

January 12, 2026

Are you looking for investment opportunities in 2026?

Topics Artificial Intelligence Economy

Stocks to Love in 2026 ↗

January 11, 2026

It's a tough act to follow.

Topics ETFs Initial Public Offering

Can This Stock Double Again in 2026? ↗

January 11, 2026

It's time to start thinking strategically -- and even philosophically -- about how seemingly similar funds are actually quite different.

Is the Schwab U.S. Dividend Equity ETF a Buy Now? ↗

January 11, 2026

It has strong momentum thanks to its current portfolio and several catalysts on the horizon.

Topics ETFs Stocks

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

This Healthcare Stock Could Be One of the Best Companies to Own in 2026 ↗

January 11, 2026

Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?

January 09, 2026

Novo Nordisk shares inch higher as the pharma giant announces an oral Wegovy partnership with Amazon Pharmacy. Here’s why NVO stock is worth owning at current levels.

Via Barchart.com

Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 09, 2026

In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive...

Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge

January 09, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by...

The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance

January 09, 2026

As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company...

As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic...

Topics Economy

The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)

January 09, 2026

Via PredictStreet

Topics Earnings Economy Intellectual Property

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

January 09, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its...

As of January 9, 2026, WW International, Inc. (NASDAQ: WW), better known as WeightWatchers, stands at the most pivotal juncture in its 63-year history. After a tumultuous 2024 and 2025 that saw the...

Topics Intellectual Property

The WeightWatchers Rebirth: A Clinical Transformation and the GLP-1 Era

January 09, 2026

Via PredictStreet

Topics Artificial Intelligence Bankruptcy

Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight ↗

January 09, 2026

Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz alone in a late-stage trial.

Via Benzinga

The Great Rotation: Investors Pivot to Defensive Moats as Tech Giants Face 'AI ROI' Audit

January 08, 2026

As the first full trading week of 2026 comes to a close, a seismic shift is rattling Wall Street. The high-flying technology sector, which dominated the market narrative throughout 2024 and 2025, is...

The tech-heavy Nasdaq Composite faced a stark reversal on January 8, 2026, as a wave of profit-taking in high-flying artificial intelligence stocks, led by Nvidia (NASDAQ: NVDA), dragged the index...

Topics Artificial Intelligence Economy Stocks

Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value

January 08, 2026

U.S. Trade Deficit Plummets to 2009 Levels as 'Liberation Day' Tariffs and Gold Surge Reshape Global Trade

Topics Artificial Intelligence Economy Stocks

January 08, 2026

On January 8, 2026, the U.S. Bureau of Economic Analysis and the Census Bureau released a landmark report revealing that the nation’s trade deficit has narrowed to its lowest level since the height of...

The start of 2026 has brought a cold front to Silicon Valley as Apple Inc. (NASDAQ:AAPL) shares retreated 7% from their December all-time highs. This downturn, which has wiped out over $200 billion in...

Topics Economy Supply Chain World Trade

Apple Shares Retreat 7% as Memory Cost Surge and 'Great Rotation' Reset Tech Valuations

January 08, 2026

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

Topics Artificial Intelligence Earnings Economy

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today ↗

Topics Intellectual Property

January 08, 2026

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.

Ventyx’s $1.2B Buyout By Eli Lilly Proves Timing Often Beats Conviction In Biotech Investing — A VC Explains ↗

Topics ETFs Government Stocks

January 07, 2026

Bottom buyers saw over 2,000% gains, while IPO investors merely broke even after a 90% drawdown, according to Atlas Venture’s Bruce Booth.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with...

Topics Initial Public Offering

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

January 07, 2026

Via StockStory

Topics Artificial Intelligence Intellectual Property

How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine ↗

January 07, 2026

Eli Lilly's plan to buy Ventyx for $1.2 billion benefits more than the takeover target, an analyst said Thursday.

Via Investor's Business Daily

Eli Lilly Confirms Plan To Buy Ventyx Biosciences In $1.2 Billion Deal ↗

January 07, 2026

Eli Lilly confirmed its $1.2 billion plan late Wednesday to acquire Ventyx Biosciences. Ventyx stock ran up nearly 40%.

Via Investor's Business Daily

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

Topics Artificial Intelligence Economy Intellectual Property

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

Lilly will acquire all of the outstanding shares of Ventyx for $14 per share of common stock in an all-cash transaction.

Topics Economy

Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal ↗

January 07, 2026